Minagawa Yukihisa, Kigawa Junzo, Kanamori Yasunobu, Itamochi Hiroaki, Terakawa Naoki, Okada Makoto, Kitada Fuminori
Department of Obstetrics and Gynecology, Tottori Prefectural Central Hospital, 730 Ezu, Tottori 680-0901, Japan.
Gynecol Oncol. 2006 Jun;101(3):495-8. doi: 10.1016/j.ygyno.2005.11.020. Epub 2006 Jan 10.
To determine the feasibility of docetaxel-cisplatin combination therapy compared with docetaxel-carboplatin combination therapy as first-line chemotherapy for patients with ovarian cancer.
Fifty patients with International Federation of Gynecology and Obstetrics stage Ic-IV ovarian cancer who underwent primary surgery were randomly assigned to receive treatment with docetaxel-cisplatin (n = 23) or docetaxel-carboplatin (n = 27). Docetaxel 70 mg/m2 and cisplatin 60 mg/m2 or carboplatin to an area under the curve of 5 were administered consecutively on Day 1 of a 3-week cycle, for 3 cycles in patients with stage Ic-II cancer and for over 5 cycles in patients with stage III-IV cancer. Patients were evaluated for treatment-related toxicity in each cycle using the National Cancer Institute Common Toxicity Criteria version 2.0.
Five patients (2 in the docetaxel-cisplatin arm and 3 in the docetaxel-carboplatin arm) discontinued the treatment at the end of the second course of chemotherapy because of apparent disease progression; however, no patients came off the protocol therapy because of treatment-related toxicity. Overall, 103 cycles of docetaxel-cisplatin treatment and 130 cycles of docetaxel-carboplatin treatment were delivered. The major toxicity was neutropenia in both regimens. The total incidence of grades 3 and 4 neutropenia was 83% (19/23) in the docetaxel-cisplatin arm and 96% (26/27) in the docetaxel-carboplatin arm. The incidence of grade 4 neutropenia was significantly lower in the docetaxel-cisplatin arm [39% (9/23) versus 74% (20/27)].
Docetaxel-cisplatin combination therapy may be feasible as first-line chemotherapy for patients with ovarian cancer.
确定多西他赛-顺铂联合疗法与多西他赛-卡铂联合疗法作为卵巢癌患者一线化疗方案的可行性。
50例接受初次手术的国际妇产科联盟（FIGO）Ic-IV期卵巢癌患者被随机分配接受多西他赛-顺铂治疗（n = 23）或多西他赛-卡铂治疗（n = 27）。在3周周期的第1天连续给予多西他赛70mg/m²和顺铂60mg/m²或曲线下面积为5的卡铂，Ic-II期癌症患者治疗3个周期，III-IV期癌症患者治疗超过5个周期。使用美国国立癌症研究所通用毒性标准第2.0版评估患者每个周期的治疗相关毒性。
5例患者（多西他赛-顺铂组2例，多西他赛-卡铂组3例）在第二疗程化疗结束时因明显疾病进展而停止治疗；然而，没有患者因治疗相关毒性而退出方案治疗。总体而言，共进行了103个周期的多西他赛-顺铂治疗和130个周期的多西他赛-卡铂治疗。两种方案的主要毒性均为中性粒细胞减少。多西他赛-顺铂组3/4级中性粒细胞减少的总发生率为83%（19/23），多西他赛-卡铂组为96%（26/27）。多西他赛-顺铂组4级中性粒细胞减少的发生率显著更低[39%（9/23）对74%（20/27）]。
多西他赛-顺铂联合疗法作为卵巢癌患者的一线化疗方案可能是可行的。
